Fagron to pay $22.5 mln to settle U.S. allegations over inflated prices
07/11/2019 17:33
WASHINGTON, Nov 7 (Reuters) - Pharmaceutical supplier Fagron
Holding USA LLC will pay $22.5 million to resolve allegations
that its subsidiaries inflated average wholesale prices for
compound drug ingredients and submitted fraudulent claims to
federal healthcare programs, the U.S. Department of Justice said
on Thursday.
The settlement will resolve legal actions filed against
Fagron units Freedom Pharmaceuticals, B&B pharmaceuticals and
Pharmacy Services Inc, the department said in a statement.
Fagron Holding is owned by Fagron NV FAGRO.BR
(Reporting by Susan Heavey and Tim Ahmann)
((202-898-8300; Reuters Messaging:
susan.heavey.thomsonreuters.com@reuters.net))